(RTTNews) - Thursday, Galderma (GALD.SW) presented new three-year data from the ARCADIA long-term extension study showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis (AD).
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.